GH Therapy in Non–Growth Hormone-Deficient Children
Before 1985, growth hormone (GH) was extracted from human pituitaries, and its therapeutic use was limited to children with severe GH deficiency (GHD). The availability of an unlimited amount of recombinant GH (rhGH) allowed for investigating the efficacy of its therapeutic use in a number of condit...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/12/1/3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588871498465280 |
|---|---|
| author | Chiara Guzzetti Anastasia Ibba Valeria Incandela Sandro Loche |
| author_facet | Chiara Guzzetti Anastasia Ibba Valeria Incandela Sandro Loche |
| author_sort | Chiara Guzzetti |
| collection | DOAJ |
| description | Before 1985, growth hormone (GH) was extracted from human pituitaries, and its therapeutic use was limited to children with severe GH deficiency (GHD). The availability of an unlimited amount of recombinant GH (rhGH) allowed for investigating the efficacy of its therapeutic use in a number of conditions other than GHD. Nowadays, patients with Turner syndrome, <i>SHOX</i> deficiency, Noonan syndrome, Prader–Willi syndrome, idiopathic short stature, chronic kidney disease, and children born small for gestational age can be treated with rhGH in order to improve adult height. In patients with Prader–Willi syndrome, rhGH therapy also improves body composition and cognitive function. Large post-marketing multinational studies in a large number of pediatric patients demonstrated a good safety profile for rhGH. Recently, long-acting formulations of rhGH have been approved and licensed for GHD, and clinical trials are ongoing for other conditions. In this paper, we review the rhGH therapy in children with conditions other than GHD. |
| format | Article |
| id | doaj-art-ead16810557e47f197361bb85c23a022 |
| institution | Kabale University |
| issn | 2227-9067 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj-art-ead16810557e47f197361bb85c23a0222025-01-24T13:26:57ZengMDPI AGChildren2227-90672024-12-01121310.3390/children12010003GH Therapy in Non–Growth Hormone-Deficient ChildrenChiara Guzzetti0Anastasia Ibba1Valeria Incandela2Sandro Loche3SSD Pediatric Endocrinology and Neonatal Screening Centre, Microcitemico Pediatric Hospital, 09121 Cagliari, ItalySSD Pediatric Endocrinology and Neonatal Screening Centre, Microcitemico Pediatric Hospital, 09121 Cagliari, ItalySSD Pediatric Endocrinology and Neonatal Screening Centre, Microcitemico Pediatric Hospital, 09121 Cagliari, ItalyResearch Area for Innovative Therapy in Endocrinology, Bambino Gesù Children Hospital, IRCCS, 00165 Rome, ItalyBefore 1985, growth hormone (GH) was extracted from human pituitaries, and its therapeutic use was limited to children with severe GH deficiency (GHD). The availability of an unlimited amount of recombinant GH (rhGH) allowed for investigating the efficacy of its therapeutic use in a number of conditions other than GHD. Nowadays, patients with Turner syndrome, <i>SHOX</i> deficiency, Noonan syndrome, Prader–Willi syndrome, idiopathic short stature, chronic kidney disease, and children born small for gestational age can be treated with rhGH in order to improve adult height. In patients with Prader–Willi syndrome, rhGH therapy also improves body composition and cognitive function. Large post-marketing multinational studies in a large number of pediatric patients demonstrated a good safety profile for rhGH. Recently, long-acting formulations of rhGH have been approved and licensed for GHD, and clinical trials are ongoing for other conditions. In this paper, we review the rhGH therapy in children with conditions other than GHD.https://www.mdpi.com/2227-9067/12/1/3childrengrowth hormoneTurner syndromeSHOX deficiencyNoonan syndromePrader–Willi syndrome |
| spellingShingle | Chiara Guzzetti Anastasia Ibba Valeria Incandela Sandro Loche GH Therapy in Non–Growth Hormone-Deficient Children Children children growth hormone Turner syndrome SHOX deficiency Noonan syndrome Prader–Willi syndrome |
| title | GH Therapy in Non–Growth Hormone-Deficient Children |
| title_full | GH Therapy in Non–Growth Hormone-Deficient Children |
| title_fullStr | GH Therapy in Non–Growth Hormone-Deficient Children |
| title_full_unstemmed | GH Therapy in Non–Growth Hormone-Deficient Children |
| title_short | GH Therapy in Non–Growth Hormone-Deficient Children |
| title_sort | gh therapy in non growth hormone deficient children |
| topic | children growth hormone Turner syndrome SHOX deficiency Noonan syndrome Prader–Willi syndrome |
| url | https://www.mdpi.com/2227-9067/12/1/3 |
| work_keys_str_mv | AT chiaraguzzetti ghtherapyinnongrowthhormonedeficientchildren AT anastasiaibba ghtherapyinnongrowthhormonedeficientchildren AT valeriaincandela ghtherapyinnongrowthhormonedeficientchildren AT sandroloche ghtherapyinnongrowthhormonedeficientchildren |